Germany-based health tech company apoQlar raised an undisclosed amount in a funding round led by YZR Capital and formed partnerships to improve surgical care.

The company intends to use the funding to improve its AR technology, expand its market presence, and scale globally. The investment will also facilitate the scaling of VSI HoloMedicine version 2.0, a software aimed at enhancing surgical planning and medical education. Furthermore, the funds will bolster apoQlar's collaborations with healthcare providers and surgical teams to improve patient outcomes and surgical practices.

apoQlar has partnered with the National University Health System (NUHS), Singtel, Infocomm Media Development Authority (IMDA), and Microsoft in Singapore to implement the HoloMedicine ASAP architecture under the NUHS HoloMedicine Program. This initiative uses Azure private multi-access edge compute (MEC), Azure’s private cloud, and 5G technology. This technology integration allows surgeons to use the VSI HoloMedicine platform through MR headsets like HoloLens 2 and other XR devices.

Analyst QuickTake: In December 2022 , apoQlar received FDA 510(k) Class II clearance for its MR software platform, VSI HoloMedicine. As a result, the US is the 30th country in which apoQlar received medical certification and has begun distribution of the device for clinical use starting in Florida from Q2 2023.